Dr. Hausman Addressed How Precision Genomics mRNA technology can be a real breakthrough for significant chronic diseases.
SPARKS, NV / ACCESSWIRE / November 16, 2022 / Precision Genomics, a Ludwig Enterprise Company (OTC:LUDG), is pleased to announce a SEQUIRE Spotlight featuring Dr. Marvin S. Hausman M.D. SEQUIRE Spotlight- Host Jonathan Miller interviews Chief Science Officer: Dr. Marvin S. Hausman. The featured interview includes in-depth information about the company’s recent patent filing, upcoming bladder cancer study and the companies moves towards filing an S1, a mini-IPO with the SEC, with the eventual goal to uplist to the NASDAQ market. This comprehensive interview explains how Precision Genomics’ groundbreaking technology could revolutionize the way we diagnose and treat today’s most prevalent diseases such as cancer, heart disease and even long Covid. All of these conditions have chronic inflammation as an underlying causative problem and health issue.
Dr. Hausman starts by discussing the company’s recent patent filing for a new method of diagnosing and treating chronic inflammation. This is a major breakthrough because chronic inflammation is at the root of many of today’s most prevalent chronic diseases, including cancer, heart disease, and even long Covid. The new method uses a buccal (cheek) swab test to measure levels of genetic inflammatory biomarkers that are indicative of chronic inflammation. A personalized genetic inflammatory signature is generated. This signature has the potential to diagnose a disease as well as monitor a person’s therapeutic response to treatment.
Dr. Hausman then discusses the company’s upcoming bladder cancer study in which the new technology will evaluated in the prediction of bladder cancer occurrence and a patient’s response to anticancer therapy.
Finally, Dr. Hausman discusses the company’s plans to file an S1 with the SEC in order to uplist Ludwig Enterprises to the NASDAQ market. This is a major milestone for the company and will allow it to raise capital to fund its continued growth and expansion. The S1 is expected to be filed in the next few weeks, and the company is confident that it will be approved by the SEC.
This SEQUIRE Spotlight featuring Dr. Marvin Hausman is a must-listen for anyone interested in Precision Genomics and the potential impact of its breakthrough genetic technology on the healthcare industry. In just under 30 minutes, Dr. Hausman covers a lot of ground, including the company’s recent patent filing, upcoming bladder cancer study, and plans to file an S1 with the SEC. If you’re looking for an in-depth overview of an up-and-coming biotech company, and the potential implications of genetic technology for the future of healthcare, this interview is definitely worth a listen!
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammationand potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and its My RNA for Life™ product line of nutraceuticals.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig’s innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiaries Precision Genomics, Inc and mRNAforLife, Inc. are poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
For Scientific Related Inquiries
Dr. Marvin S. Hausman MD
Chief Science Officer
503-327-4173
[email protected]
For Business Related Inquiries
Luke J. Fannon
484-429-5846
[email protected]
SOURCE: Ludwig Enterprises, Inc.